Pain Management · OpioidRegulatory Approvalregulatorymid-term

FDA Accepts Supplemental NDA for Percodan by Endo Operations

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/26/2026, 6:31:21 PM

Assessment confidence: 71% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental NDA for Percodan is significant as it may strengthen Endo Operations' competitive position in the opioid pain management market. This development necessitates close monitoring of market dynamics and potential responses from competitors. Regulatory context from FDA (FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose) supports the near-term read. Assessment grounded in 8 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential market impact and competitive response from other opioid manufacturers. The strongest clinical anchor is Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain (ClinicalTrials.gov), sub-indication match (pain). In pain, 3 regulatory and 1 competitive items passed relevance filtering for Percodan.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approval for Oxycodone Hydrochloride by Novel Labs (Humanexa Signals) — sub-indication match (pain). This acceptance may enhance Endo Operations' position in the pain management market, particularly in the opioid segment.

Regulatory Outlook

Regulatory risk is concentrated around FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose (FDA). Sub-indication match (pain). The acceptance of the supplemental NDA indicates a positive regulatory trajectory for Percodan, which could influence future approvals and compliance strategies in the opioid category.

Key Risks

Elevated medium regulatory exposure for Percodan could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The approval could lead to increased market share for Endo Operations in the opioid segment, impacting revenue streams and competitive positioning against other pain management products.
Upside for Percodan may improve if Oropharyngeoesophageal Topical Anesthesia Versus Intravenous Propofol -Ketamine Sedation for Upper Gastrointestinal Endoscopy (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the potential market impact and competitive response from other opioid manufacturers.

What Would Change This Assessment

This becomes more urgent if Monitor for further updates on the approval timeline and any competitive reactions from other pain management products.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
FDAhigh relevance
Sub-indication match (pain)
FDA document
View source
FDA AP — PERCODAN (SUPPL)
FDAmedium relevance
Entity match (percodan); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PERCODAN (SUPPL)
FDAmedium relevance
Entity match (percodan); Regulatory pathway relevance (nda)
FDA document
View source
First GLP-1 tablet for weight loss approved in the UK
MHRAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — VANTAS (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
Notice: Register of authorised online sellers of medicines in Northern Ireland
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Evaluation of the Japet.W+ Medical Device for Low Back Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Oropharyngeoesophageal Topical Anesthesia Versus Intravenous Propofol -Ketamine Sedation for Upper Gastrointestinal Endoscopy
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Pelvic Pain in Women With Endometriosis
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
ENDO1000 - A UK-wide Endometriosis Research Project
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Study Title: A Multicenter, Prospective, Modified Platform Trial Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Approval for Oxycodone Hydrochloride by Novel Labs
Humanexa Signalsmedium relevance
Sub-indication match (pain)
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalslow relevance
Sponsor/company relevance (Roche)

Warm intranasal saline irrigation reduces intraoperative blood loss during functional endoscopic sinus surgery: a propensity score-matched cohort study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Progestin therapy in premenopausal women with incidental meningioma-a narrative review and recommendations for women's health specialists.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Percodan
pain management sector

Commercial impact

medium

The approval could lead to increased market share for Endo Operations in the opioid segment, impacting revenue streams and competitive positioning against other pain management products.

Regulatory impact

medium

The acceptance of the supplemental NDA indicates a positive regulatory trajectory for Percodan, which could influence future approvals and compliance strategies in the opioid category.

What to watch

Monitor for further updates on the approval timeline and any competitive reactions from other pain management products.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.